Department of Internal Medicine, Neurology and Dermatology, Clinic for Gastroenterology and Rheumatology, Rheumatology Unit, University of Leipzig, Liebigstrasse 20, 04103 Leipzig, Germany.
Expert Rev Clin Immunol. 2014 May;10(5):557-71. doi: 10.1586/1744666X.2014.904746. Epub 2014 Apr 9.
Prednisone is an old and very valuable drug in clinical use for over 60 years by now. It is well known by physicians and widely used for different kinds of inflammatory states including rheumatoid arthritis (RA). Clinical trials during the last 20 years have changed its clinical use, particularly with regards to dosage. Today, rheumatologists are treating their patients much more likely over a long period of time using a low-dose scheme. The effectiveness and safety of this low-dose use is the objective of the current clinical research and shall be enlightened in this drug profile. It is also featuring current knowledge about the value of modified-release prednisone with regards to the just published results of the 2nd Circadian Administration of Prednisone in Rheumatoid Arthritis trial. Moreover, the mechanisms of action of prednisone and its relatives will be summed up.
泼尼松是一种在临床上使用超过 60 年的古老而非常有价值的药物。它为医生所熟知,并广泛用于治疗各种炎症状态,包括类风湿关节炎(RA)。过去 20 年的临床试验改变了其临床用途,特别是在剂量方面。如今,风湿病医生更有可能在很长一段时间内使用低剂量方案来治疗患者。这种低剂量使用的有效性和安全性是当前临床研究的目标,并将在本药物简介中阐明。它还介绍了关于刚刚发表的类风湿关节炎中泼尼松的第二 circadian 给药试验的结果的关于改良释放泼尼松的价值的当前知识。此外,还总结了泼尼松及其类似物的作用机制。